Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening

Document Type

Article

Publication Title

Current oncology (Toronto, Ont.)

Abstract

Pancreatic cancer (PC) is a highly malignant and aggressive tumor. Despite medical advancement, the silent nature of PC results in only 20% of all cases considered resectable at the time of diagnosis. It is projected to become the second leading cause in 2030. Most pancreatic cancer cases are diagnosed in the advanced stages. Such cases are typically unresectable and are associated with a 5-year survival of less than 10%. Although there is no guideline consensus regarding recommendations for screening for pancreatic cancer, early detection has been associated with better outcomes. In addition to continued utilization of imaging and conventional tumor markers, clinicians should be aware of novel testing modalities that may be effective for early detection of pancreatic cancer in individuals with high-risk factors. The pathogenesis of PC is not well understood; however, various modifiable and non-modifiable factors have been implicated in pancreatic oncogenesis. PC detection in the earlier stages is associated with better outcomes; nevertheless, most oncological societies do not recommend universal screening as it may result in a high false-positive rate. Therefore, targeted screening for high-risk individuals represents a reasonable option. In this review, we aimed to summarize the pathogenesis, genetic risk factors, high-risk population, and screening modalities for PC.

First Page

8693

Last Page

8719

DOI

10.3390/curroncol29110686

Publication Date

11-15-2022

Identifier

36421339 (pubmed); PMC9689647 (pmc); 10.3390/curroncol29110686 (doi); curroncol29110686 (pii)

This document is currently not available here.

Share

COinS